Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Quality of diabetes treatment in four orthopaedic departments in the Capital Region of Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lyme arthritis is rare in Eastern Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Heterogenicity in hospital service for children and adolescents with functional somatic symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A major outbreak of covid-19 at a residential care home

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Reduction in maternal mortality in Denmark over three decades

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Surgical management of rhinocerebral mucormycosis: A case series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Iatrogenic cerebral radiation necrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: The aim was to describe tumour response, complications, recurrence and survival after hyperthermic isolated limb perfusion (ILP) with melphalan or melphalan in combination with tumour necrosis factor-alpha in patients with melanoma metastases confined to an extremity.

MATERIAL AND METHODS: A total of 84 perfusions were performed (53 women, 31 men, median age 63 years) from 1993 to 2010. 95% of the perfusions were administered to the lower limbs and 5% to the upper limbs. The inclusion criteria were recurrent and/or clinically apparent cutaneous/subcutaneous extremity in-transit melanoma metastases.

RESULTS: The response rate after ILP was 85%; 42% had complete response (CR), 43% partial response (PR), 12% no change (NC) and 3% progression. Two- and five-year survival rates were 57% and 31%, respectively, and they were higher for patients with than without lymph node metastases. Time from ILP to recurrence was a median of seven months (range 1-37 months) for patients with CR or PR. Survival was longer for patients with CR or PR than for patients showing NC or progression. Several patients had mild or moderate local toxicity reactions, two patients developed severe local toxicity.

CONCLUSION: ILP induces tumour regression in the vast majority of patients. One patient, i.e. 1% of the group, died from surgical complications. Otherwise, ILP treatment had an acceptable morbidity in this group of very sick patients. We are convinced that the treatment should be offered to improve local disease control in patients with multiple and/or recurrent melanoma confined to an extremity if surgical excision is not possible.

FUNDING: not relevant.

TRIAL REGISTRATION: not relevant.

OriginalsprogEngelsk
TidsskriftDanish Medical Bulletin (Online)
Vol/bind61
Udgave nummer1
Sider (fra-til)A4741
ISSN1603-9629
StatusUdgivet - jan. 2014

ID: 44382035